Therapeutic strategies for the treatment of spinal muscular atrophy

Future Medicinal Chemistry

Volumn 4, Issue 13, 2012, Pages 1733-1750

  Cherry, Jonathan J ^a   Androphy, Elliot J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; AMIDE; AMINOGLYCOSIDE; ANTISENSE OLIGONUCLEOTIDE; CANTHARIDIN; CEFTRIAXONE; DIHYDROQUINOLINONE; FASUDIL; HETEROCYCLIC COMPOUND; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; INDOPROFEN; INTRONIC SPLICING SILENCER N1 ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA PRECURSOR; NEUROPROTECTIVE AGENT; OLESOXIME; PARVOVIRUS VECTOR; PHENYLBUTYRATE; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RG 3039; RILUZOLE; SALBUTAMOL; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANADATE SODIUM; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ADENO ASSOCIATED VIRUS; ALTERNATIVE RNA SPLICING; AMYOTROPHIC LATERAL SCLEROSIS; CELL CULTURE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG TARGETING; DRUG WITHDRAWAL; EMBRYONIC STEM CELL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENE REPLACEMENT THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULARLY TARGETED THERAPY; MOTONEURON; MOTOR NEURON DISEASE; MUSCLE STRENGTH; NEURAL STEM CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF COMPLEMENTARY ADENO ASSOCIATED VIRUS 9; SPINAL CORD; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; NEUROPROTECTIVE AGENTS; SMN COMPLEX PROTEINS;

EID: 84865768592     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.107     Document Type: Review

References (161)

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 15(6), 409-413 (1978).
2. McAndrew, PE, DW Parsons, LR Simard et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet. 60, 1411-1422 (1997).
3. Crawford TO, CA Pardo. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3(2), 97-110 (1996).
4. Lefebvre S, L Burglin, S Reboullet et al. Identification and characterization of a spinal muscular atrophy determining gene. Cell 80, 155-165 (1995).
5. DiDonato CJ, SE Ingraham, JR Mendell et al. Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity? Ann. Neurol. 41, 230-237 (1997).
6. Wirth, B, T Schmidt, E Hahnen et al. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am. J. Hum. Genet. 61(5), 1102-1111 (1997).
7. Pearn J. Classification of spinal muscular atrophies. Lancet 1(8174), 919-922 (1980).
8. Russman, BS, Spinal muscular atrophy: clinical classification and disease heterogeneity. J. Child Neurol. 22(8), 946-951 (2007).
9. Brzustowicz, LM, T Lehner, L Castilla et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 344, 540-541 (1990).
10. Melki J, S Lefebvre, L Burglen et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science 264, 1474-1477 (1994).
11. Gilliam TC, LM Brzustowicz, LH Castilla et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 345(6278), 823-825 (1990).
12. Echaniz-Laguna A, Miniou P, Bartholdi D et al. The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am. J. Hum. Genet. 64(5), 1365-1370 (1999).
13. Monani UR, Lorson CL, Parsons DW et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8(7), 1177-1183 (1999).
14. Boda B, Mas C, Giudicelli C et al. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Eur. J. Hum. Genet. 12(9), 729-737 (2004).
15. Jablonka S, Rossoll W, Schrank B et al. The role of SMN in spinal muscular atrophy. J. Neurol. 247(Suppl. I), I37-I42 (2000).
16. Lorson CL, Hahnen E, Androphy EJ et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96(11), 6307-6311 (1999).
17. Gennarelli M, Lucarelli M, Capon F et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem. Biophys. Res. Commun. 213, 342-348 (1995).
18. Gavrilov DK, Shi XY, Das K et al. Differential SMN2 expression associated with SMA severity. Nat. Genet. 20(3), 230-231 (1998).
19. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet. 9(2), 259-265 (2000).
20. Lorson CL, Strasswimmer J, Yao J-M et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19, 63-66 (1998).
21. Burnett BG, Munoz E, Tandon A et al. Regulation of SMN protein stability. Mol. Cell. Biol. 29(5), 1107-1115 (2009).
22. Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp. Cell Res. 296(1), 51-56 (2004).
23. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin. Pediatr. Neurol. 13(2), 121-131 (2006).
24. Coady TH, Lorson CL. SMN in spinal muscular atrophy and snRNP biogenesis. Wiley Interdiscip. Rev. RNA 2(4), 546-564 (2011).
25. Coovert D, Le T, McAndrew P et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Gen. 6, 1205-1214 (1997).
26. Gabanella F, Carissimi C, Usiello A et al. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum. Mol. Genet. 14(23), 3629-3642 (2005).
27. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555-3565 (1996).
28. Liu Q, Fischer U, Wang F et al. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 90(6), 1013-1021 (1997).
29. Pellizzoni L, Charroux B, Dreyfuss G. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc. Natl Acad. Sci. USA 96(20), 11167-11172 (1999).
30. Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298(5599), 1775-1779 (2002).
31. Meister G, Buhler D, Laggerbauer B et al. Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins. Hum. Mol. Genet. 9(13), 1977-1986 (2000).
32. Jablonka S, Bandilla M, Wiese S et al. Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Hum. Mol. Genet. 10(5), 497-505 (2001).
33. Fan L, Simard LR. Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum. Mol. Genet. 11(14), 1605-1614 (2002).
34. Zhang HL, Pan F, Hong D et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J. Neurosci. 23(16), 6627-6637 (2003).
35. Peter CJ, Evans M, Thayanithy V et al. The COPI vesicle complex binds and moves with survival motor neuron within axons. Hum. Mol Genet. 20(9), 1701-1711 (2011).
36. Rossoll W, Jablonka S, Andreassi C et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of {beta}-actin mRNA in growth cones of motoneurons. J. Cell. Biol. 163(4), 801-812 (2003).
37. McWhorter ML, Monani UR, Burghes AH et al. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 162(5), 919-931 (2003).
38. Lefebvre S, Burlet P, Liu Q et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Gene. 16, 265-269 (1997).
39. Selig S, Bruno S, Scharf JM et al. Expressed cadherin pseudogenes are localized to the critical region of the spinal muscular atrophy gene. Proc. Natl Acad. Sci. USA 92(9), 3702-3706 (1995).
40. Theodosiou AM, Morrison KE, Nesbit AM et al. Complex repetitive arrangements of gene sequence in the candidate region of the spinal muscular atrophy gene in 5q13. Am. J. Hum. Genet. 55(6), 1209-1217 (1994).
41. Francis MJ, Nesbit MA, Theodosiou AM et al. Mapping of retrotransposon sequences in the unstable region surrounding the spinal muscular atrophy locus in 5q13. Genomics 27(2), 366-369 (1995).
42. Feldkotter M, Schwarzer V, Wirth R et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70(2), 358-368 (2002).
43. Prior TW, Swoboda KJ, Scott HD et al. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am. J. Med. Genet. 130A(3), 307-310 (2004).
44. Parano E, Pavone L, Falsaperla R et al. Molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy. Ann. Neurol. 40(2), 247-251 (1996).
45. Hsieh-Li HM, Chang JG, Jong YJ et al. A mouse model for spinal muscular atrophy. Nat. Genet. 24(1), 66-70 (2000).
46. Monani UR, Sendtner M, Coovert DD et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9(3), 333-339 (2000).
47. Michaud M, Arnoux T, Bielli S et al. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis. 38(1), 125-135 (2010).
48. Schrank B, Gotz R, Gunnersen J et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 94, 9920-9925 (1997).
49. Cummings BJ, Uchida N, Tamaki SJ et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc. Natl Acad. Sci. USA 102(39), 14069-14074 (2005).
50. Nistor GI, Totoiu MO, Haque N et al. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49(3), 385-396 (2005).
51. Keirstead HS, Nistor G, Bernal G et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 25(19), 4694-4705 (2005).
52. Yan J, Xu L, Welsh AM et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med. 4(2), e39 (2007).
53. Rossi SL, Nistor G, Wyatt T et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS ONE 5(7), e11852 (2010).
54. Le TT, Pham LT, Butchbach ME et al. SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14(6), 845-857 (2005).
55. Corti S, Nizzardo M, Nardini M et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J. Clin. Invest. 118(10), 3316-3330 (2008).
56. Corti S, Nizzardo M, Nardini M et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 133(Pt 2), 465-481 (2010).
57. Amariglio N, Hirshberg A, Scheithauer BW et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6(2), e1000029 (2009).
58. Foust KD, Nurre E, Montgomery CL et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27(1), 59-65 (2009).
59. Foust KD, Wang X, McGovern VL et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28(3), 271-274 (2010).
60. Monani UR, Pastore MT, Gavrilina TO et al. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J. Cell Biol. 160(1), 41-52 (2003).
61. Valori CF, Ning K, Wyles M et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2(35), 35-42 (2010).
62. Dominguez E, Marais T, Chatauret N et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20(4), 681-693 (2011).
63. Mattar CN, Waddington SN, Biswas A et al. Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther. doi:10.1038/gt.2011.216 (2012) (Epub ahead of print).
64. Passini MA, Bu J, Roskelley EM et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120(4), 1253-1264 (2010).
65. Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res. 35(2),371-389 (2006).
66. Singh NK, Singh NN, Androphy EJ et al. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell Biol. 26(4), 1333-1346 (2006).
67. Singh NN, Androphy EJ, Singh RN. The regulation and regulatory activities of alternative splicing of the SMN gene. Crit. Rev. Eukaryot. Gene Expr. 14(4), 271-285 (2004).
68. Singh NN, Androphy EJ, Singh RN. An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem. Biophys. Res. Commun. 315(2), 381-388 (2004).
69. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA 10(8), 1291-1305 (2004).
70. Cartegni L, Hastings ML, Calarco JA et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 78(1), 63-77 (2006).
71. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30(4), 377-384 (2002).
72. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34(4), 460-463 (2003).
73. Hua Y, Vickers TA, Okunola HL et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82(4), 834-848 (2008).
74. Hua Y, Sahashi K, Hung G et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24(15), 1634-1644 (2010).
75. Passini MA, Bu J, Richards AM et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3(72), 72-18 (2011).
76. Gogliotti RG, Hammond SM, Lutz C et al. Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun. 391(1), 517-522 (2010).
77. Hua Y, Sahashi K, Rigo F et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478(7367), 123-126 (2011).
78. Porensky PN, Mitrpant C, McGovern VL et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 21(7), 1625-1638 (2012).
79. Zarate CA, Manji HK. Riluzole in psychiatry: a systematic review of the literature. Exp. Opin. Drug Metab. Toxicol. 4(9), 1223-1234 (2008).
80. Haddad H, Cifuentes-Diaz C, Miroglio A et al. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 28(4), 432-437 (2003).
81. Russman BS, Iannaccone ST, Samaha FJ. A Phase I trial of riluzole in spinal muscular atrophy. Arch. Neurol. 60(11), 1601-1603 (2003).
82. Bordet T, Buisson B, Michaud M et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322(2), 709-720 (2007).
83. Bordet T, Buisson B, Michaud M et al. Specific antinociceptive activity of cholest-4- en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J. Pharmacol. Exp. Ther. 326(2), 623-632 (2008).
84. Rothstein JD, Patel S, Regan MR et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433(7021), 73-77 (2005).
85. Nizzardo M, Nardini M, Ronchi D et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp. Neurol. 229(2), 214-225 (2011).
86. Lewerenz J, Albrecht P, Tien ML et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem, 111(2), 332-343 (2009).
87. Jarecki J, Chen X, Bernardino A et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14(14), 2003-2018 (2005).
88. Lunn MR, Root DE, Martino AM et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem. Biol. 11(11), 1489-1493 (2004).
89. Zhang, ML, Lorson CL, Androphy EJ et al. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther, 8(20), 1532-1538 (2001).
90. Andreassi C, Jarecki J, Zhou J et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10(24), 2841-2849 (2001).
91. Cherry JJ, Evans MC, Ni J et al. Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J. Biomol. Screen. 17(4), 481-495 (2012).
92. Xiao J, Marugan JJ, Zheng W et al. Discovery, synthesis and biological evaluation of novel SMN protein modulators. J. Med. Chem. 54(18), 6215-6233 (2011).
93. Kobayashi, DT, RJ Olson, L Sly et al. Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS ONE 6(8), e24269 (2011).
94. Makhortova NR, Hayhurst M, Cerqueira A et al. A screen for regulators of survival of motor neuron protein levels. Nat. Chem. Biol. 7(8), 544-552 (2011).
95. Evans MC, Cherry JJ, Androphy EJ. Differential regulation of the SMN2 gene by individual HDAC proteins. Biochem. Biophys. Res. Commun. 414(1), 25-30 (2011).
96. Chang JG, Hsieh-Li HM, Jong YJ et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA 98(17), 9808-9813 (2001).
97. Andreassi C, Angelozzi C, Tiziano FD et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12(1), 59-65 (2004).
98. Mercuri E, Bertini E, Messina S et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 14(2), 130-135 (2004).
99. Brichta L, Hofmann Y, Hahnen E et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12(19), 2481-2489 (2003).
100. Sumner CJ, Huynh TN, Markowitz JA et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54(5), 647-654 (2003).
101. Harahap IS, Saito T, San LP et al. Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. Brain. Dev. 34(3), 213-222 (2012).
102. Tsai LK, Tsai MS, Ting CH et al. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J. Mol. Med. 86(11), 1243-1254 (2008).
103. Rak K, Lechner BD, Schneider C et al. Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol. Dis. 36(3), 477-487 (2009).
104. Kissel JT, Scott CB, Reyna SP et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE 6(7), e21296 (2011).
105. Swoboda KJ, Scott CB, Crawford TO et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 5(8), e12140 (2010).
106. Swoboda KJ, Scott CB, Reyna SP et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE 4(5), e5268 (2009).
107. Darbar IA, Plaggert PG, Resende MB et al. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol. 11, 36 (2011).
108. Hahnen E, Eyupoglu IY, Brichta L et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 98(1), 193-202 (2006).
109. Riessland M, Ackermann B, Forster A et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19(8), 1492-1506 (2010).
110. Habold C, Poehlmann A, Bajbouj K et al. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J. Cell. Mol. Med. 12(2), 607-621 (2008).
111. Sebastian C, Serra M, Yeramian A et al. Deacetylase activity is required for STAT5- dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J. Immunol. 180(9), 5898-5906 (2008).
112. Ting CH, Lin CW, Wen SL et al. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum. Mol. Genet. 16(5), 499-514 (2007).
113. Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell Biol. 23(12), 4162-4173 (2003).
114. Nakajima H, Brindle PK, Handa M et al. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J. 20(23), 6836-6844 (2001).
115. Avila AM, Burnett BG, Taye AA et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117(3), 659-671 (2007).
116. Narver HL, Kong L, Burnett BG et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Ann. Neurol. 64(4), 465-470 (2008).
117. Garbes L, Riessland M, Holker I et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet. 18(19), 3645-3658 (2009).
118. Riessland M, Brichta L, Hahnen E et al. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/ protein levels in spinal muscular atrophy cells. Hum. Genet. 120(1), 101-110 (2006).
119. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol. 51(7), 879-886 (1996).
120. Isoe T, Naito M, Shirai A et al. Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim. Biophys. Acta 1117(2), 131-135 (1992).
121. Farooq F, Molina FA, Hadwen J et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J. Clin. Invest. 121(8), 3042-3050 (2011).
122. Farooq F, Balabanian S, Liu X et al. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum. Mol. Genet. 18(21), 4035-4045 (2009).
123. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 8(24), 4032-4039 (2009).
124. Chen PC, Gaisina IN, El-Khodor BF et al. Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the median survival time of D7 SMA KO mouse model of spinal muscular atrophy. ACS Chem. Neurosci. 3(1), 5-11 (2012).
125. Bowerman M, Shafey D, Kothary R. Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J. Mol. Neurosci. 32(2), 120-131 (2007).
126. LuoL, O'Leary DD. Axon retraction and degeneration in development and disease. Annu. Rev. Neurosci. 28, 127-156 (2005).
127. Govek EE, Newey SE, Van Aelst L. The role of the Rho GTPases in neuronal development. Genes Dev. 19(1), 1-49 (2005).
128. Bowerman M, Murray LM, Boyer JG et al. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10, 24 (2012).
129. Bowerman M, Beauvais A, Anderson CL et al. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19(8), 1468-1478 (2010).
130. Zhang Z, Kelemen O, van Santen MA et al. Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNA. J. Biol. Chem. 286(12), 10126-10136 (2011).
131. Hua Y, Zhou J. Modulation of SMN nuclear foci and cytoplasmic localization by its C-terminus. Cell. Mol. Life Sci. 61(19-20), 2658-2663 (2004).
132. Wolstencroft EC, Mattis V, Bajer AA et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum. Mol. Genet. 14(9), 1199-1210 (2005).
133. Barton-Davis ER, Cordier L, Shoturma DI et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104(4), 375-381 (1999).
134. Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349(15), 1433-1441 (2003).
135. Bidou L, Hatin I, Perez N et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther. 11(7), 619-627 (2004).
136. Mattis VB, Rai R, Wang J et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. 120(4), 589-601 (2006).
137. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum. Mol. Genet. 18(7), 1310-1322 (2009).
138. Mattis VB, Ebert AD, Fosso MY et al. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet. 18(20), 3906-3913 (2009).
139. Mattis VB, Fosso MY, Chang CW et al. Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neurosci. 10, 142 (2009).
140. Kwon DY, Motley WW, Fischbeck KH et al. Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Hum. Mol. Genet. 20(18), 3667-3677 (2011).
141. Stevens MR. Hydroxyurea: an overview. J. Biol. Regul. Homeost. Agents 13(3), 172-175 (1999).
142. Grzeschik SM, Ganta M. TW Prior et al. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann. Neurol. 58(2), 194-202 (2005).
143. Xu C, Chen X, Grzeschik SM et al. Hydroxyurea enhances SMN2 gene expression through nitric oxide release. Neurogenetics 12(1), 19-24 (2011).
144. Liang WC, Yuo CY, Chang JG et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J. Neurol. Sci. 268(1-2), 87-94 (2008).
145. Chen TH, Chang JG, Yang YH et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 75(24), 2190-2197 (2010).
146. Singh J, Salcius M, Liu SW et al. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem. Biol. 3(11), 711-722 (2008).
147. Thurmond J, Butchbach ME, Palomo M et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem. 51(3), 449-469 (2008).
148. Butchbach ME, Singh J, Thorsteinsdottir M et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet. 19(3), 454-467 (2010).
149. Hastings ML, Berniac J, Liu YH et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci. Transl. Med. 1(5), 5-12 (2009).
150. Martineau L, Horan MA, Rothwell NJ et al. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin. Sci. (Lond.) 83(5), 615-621 (1992).
151. Maltin CA, Delday MI, Watson JS et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin. Sci. (Lond.) 84(6), 651-654 (1993).
152. Caruso JF, Signorile JF, Perry AC et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med. Sci. Sports Exerc. 27(11), 1471-1476 (1995).
153. Kissel JT, McDermott MP, Mendell JR et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57(8), 1434-1440 (2001).
154. Signorile JF, Banovac K, Gomez M et al. Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist. Arch. Phys. Med. Rehabil. 76(1), 55-58 (1995).
155. Kinali M, Mercuri E, Main M et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 59(4), 609-610 (2002).
156. Angelozzi C, Borgo F, Tiziano FD et al. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J. Med. Genet. 45(1), 29-31 (2008).
157. Pane M, Staccioli S, Messina S et al. Daily salbutamol in young patients with SMA type II. Neuromuscul. Disord. 18(7), 536-540 (2008).
158. Tiziano FD, Lomastro R, Pinto AM et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J. Med. Genet. 47(12), 856-858 (2010).
159. Inglese J, Auld DS, Jadhav A et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 103(31), 11473-11478 (2006).
160. Trophos. Trophos announces results of Phase III study of olesoxime in amyotrophic lateral sclerosis. www.trophos.com/news/pr20111213.htm
161. Families of SMA. Update on the spinal muscular atrophy drug development pipeline from Families of SMA. www.fsma.org/LatestNews/index. cfm?ID=6612&TYPE=1150